Pharmacists and stakeholders should be aware of a significant increase in calls to poison control centers related to semaglutide products used for diabetes and weight loss. From January to November 2023, poison centers reported nearly 3,000 calls involving semaglutide, a more than 15-fold increase since 2019. The majority of calls resulted from dosing errors, with patients accidentally taking double doses or incorrect amounts. Compounded versions, arising due to demand exceeding supply, have contributed to the issue. These compounded forms, frequently sold in different dosages, may lead to potential risks. Despite calls rising, it is challenging to distinguish between calls related to patented drugs and their compounded versions.